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Background: The Epstein-Barr virus (EBV) is one of the most 
common viruses found in humans, causing lifelong infection in 
up to 95% of the world population. 
Objectives: To analyze the seroprevalence of EBV infection in 
different population groups in Croatia. 
Methods: During a 2 year period (2015–2016), a total of 2022 
consecutive serum samples collected from Croatian residents 
were tested for the presence of EBV-speciﬁc viral capsid antigen 
(VCA) immunoglobulin M (IgM) and IgG antibodies using an 
enzyme-linked immunoassay. IgM/IgG-positive samples were 
further tested for IgG avidity.
Results: The overall prevalence of EBV IgG antibodies was 
91.4%. Females had signiﬁcantly higher IgG seroprevalence 
than males (93.1% vs. 89.9%, P = 0.008). According to 
age, IgG seropositivity increased progressively from 59.6% 
in children age < 9 years to 98.3% in 30–39 year olds, and 
remained stable thereafter (P < 0.001). The IgG seroprevalence 
differed signiﬁcantly among groups: 68.1% in children/
adolescents and 95.9% in adults; multiple sclerosis (100%), 
hemodialysis patients (97.7%), heart transplant recipients 
(93.8%), hematological malignancies (91.2%), and Crohn’s 
disease (88.5%), P < 0.001. IgM antibodies were detected 
in 9% of participants. Using IgG avidity, recent primary EBV 
infection was documented in 83.8% of IgM-positive subjects 
< 9 years old, 69.2% age 10–19, 33.3% age 20–29, and 3.6–
4.2% > 40. All IgM positive participants > 40 years showed high 
IgG avidity. Logistic regression showed that age is associated 
with EBV IgG seropositivity.
Conclusions: EBV is widespread in the Croatian population. 
Older age appears to be the main risk factor for EBV sero- 
positivity.
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T he Epstein-Barr virus (EBV) is a double-stranded DNA γ-herpes virus. The virus is ubiquitous, causing lifelong 
infection with high incidence in the adult world population 
(up to 95%), while in children prevalence differs widely by 
geographic region [1-3]. EBV has the unique ability to infect, 
activate, and clonally expand B lymphocytes. The virus is trans-
mitted via saliva, but it can be transmitted by blood and solid 
organ transplants or stem cell transplants as well [4]. Primary 
infection occurs mainly in early childhood or adolescence, 
with more than 50% seropositive children by the age of five. 
Following primary infection, EBV remains latent in lympho-
cytes and periodically can reactivate. Even though primary 
infection occurs within the first few years of life or in adoles-
cence and is usually asymptomatic or manifested as infectious 
mononucleosis, in some cases the virus can be implicated with 
development of different diseases. In immunocompromised 
hosts, the growth-transforming properties of EBV can result 
in malignant diseases such as hematological (non-Hodgkin’s 
disease, Hodgkin’s disease, Burkitt’s lymphoma) and gastroin-
testinal malignancies (gastric adenocarcinoma, nasopharyngeal 
carcinoma) [5]. Some studies have shown higher EBV sero-
positivity in patients with leukemia [6], while others found 
no difference in the EBV seropositivity between patients with 
hematological malignancies and the general population [7]. 
Patients with inflammatory bowel disease (IBD), including 
Crohn’s disease, are frequently immunosuppressed and thus at 
risk for severe EBV infection. There are little published data 
on the prevalence of EBV in this population group [8]. Several 
observations implicate EBV in the pathogenesis of multiple 
sclerosis, namely universal EBV seropositivity [9]. In addition, 
EBV is a significant pathogen in hemodialysis patients as well 
as in transplant patients, who can develop post-transplant lym-
phoproliferative disorder (PTLD) [4,10,11].
In Croatia, there are no data on the prevalence of EBV infec-
tion. The aim of this study is to analyze the seroprevalence of 
EBV infection in the Croatian general adult and child popu-
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lation and in different groups of patients including patients 
suffering from Crohn’s disease, multiple sclerosis, hematologic 
disorders, and hemodialysis patients. The study also analyzed 
EBV seroprevalence in those who underwent kidney or heart 
transplantation. 
PATIENTS AND METHODS
During a 2 year period (2015–2016) a total of 2022 consecu-
tive serum samples were tested for the presence of EBV viral 
capsid antigen (VCA) immunoglobulin M (IgM) and IgG anti-
bodies. IgM/IgG positive samples were further tested for IgG 
avidity to confirm or rule out primary EBV infection. Samples 
were collected from patients residing in all Croatian counties 
who were tested at two large medical institutions (University 
Hospital Centre Zagreb and Croatian National Institute of 
Public Health). In the tested group, there were 1104 males 
(54.6%) and 918 females (45.4%) aged 1–84 years [Figure 1]. 
Patients included in the study were routinely tested for hemo-
dialysis, hematologic check-up, preoperative check-up (cardiac 
and renal transplant program), elevated liver transaminases, 
lymphatic disorders, neurological disorders such as sclerosis 
multiplex, and Crohn’s disease. Specific anti-EBV VCA IgM 
and IgG antibodies were detected using a commercial enzyme-
linked fluorescent assay (ELFA; VIDAS, Bimerieux, Marcy 
l’Etoile, France) and enzyme-linked immunosorbent assay 
(ELISA; Sekisui Virotech, Rüsselsheim, Germany). Results were 
interpreted according to the manufacturer’s recommendations: 
VIDAS EBV IgM ≤ 0.11 negative, 0.12–0.18 equivocal, ≥ 0.19 
positive; VIDAS EBV VCA IgG ≤ 0.09 negative, 0.10–0.20 
equivocal, ≥ 0.21 positive; and Virotech EBV VCA IgM and 
IgG < 9 VE negative, 9–11 VE equivocal, > 11 VE positive.
IgM/IgG positive samples were further tested for IgG avidity 
to confirm or to rule out primary EBV infection using ELISA 
(Euroimmun, Lübeck, Germany). The IgG avidity index (AI) 
was calculated and expressed as a percentage using the extinc-
tion values with and without urea treatment. The interpretation 
of AI results was determined as follows: AI < 40% = low avidity 
antibodies, indicating acute primary infection; AI 40–60% = 
borderline avidity, indicating recent (post-acute) infection; 
and AI > 60% = high avidity antibodies, indicating past EBV 
infection.
STATISTICAL ANALYSIS
The frequencies are shown with 95% confidence intervals 
(95%CI). Differences between groups were assessed using chi-
square test. The strength of association between dependent and 
independent variables was assessed using logistic regression 
(crude odds ratios [OR], odds ratios adjusted for age and gen-
der [AOR]). For statistical analysis, software package STATA/
IC version 11.2 (StataCorp LP, USA) was used. The level of 
statistical significance was α = 0.05. 
RESULTS
Prevalence of EBV antibodies is presented in Table 1. The 
overall prevalence of EBV IgG antibodies was 91.4% (95%CI 
90.1–92.6). Females had significantly higher IgG seroprevalence 
than males (93.1% vs. 89.9%, P = 0.008). According to age, IgG 
seropositivity increased progressively from 59.6% in children < 
9 years of age to 98.3% in 30–39 year olds, and remained stable 
thereafter (P < 0.001). According to the population group, the 
prevalence was lowest in children/adolescents (68.1%) com-
pared to 88.5%–100% in adults and other tested population 
groups (P < 0.001).
IgM antibodies were detected in 9.0% (95%CI 7.8–10.3) of 
participants indicating acute EBV infection. There was no sig-
nificant difference in the prevalence of IgM antibodies among 
males and females (8.2% vs. 10.0%, P = 0.160). Acute infections 
were most commonly detected in age groups < 9 years (18.7%) 
and 10–19 years (22.7%). However, acute infections were 
reported in all age groups with prevalence of 10.6% in 20–29 
year olds, 7.3% in 30–39 year olds, and 3.6–4.2% in persons > 40 
years. Using IgG avidity, acute primary EBV infections (low AI) 
were detected in 83.8% participants in the age group < 10 years, 
69.2% in the 10–19 age group, 33.3% in the 20–29 age group, 
and 4.0% in the 30–39 age group. All IgM positive participants 
older than 40 years showed high AI [Figure 2].
Results of logistic regression showed that older age was a 
significant risk factor for the EBV IgG seropositivity: 10–19 
year age group OR = 2.556 (95%CI 1.669–3.915), 60+ year age 
group OR = 40.448 (95%CI 17.149-94.882) [Table 2].
DISCUSSION
A large proportion of the adult world population is seropositive 
to EBV; however, in children there are significant geographic 
Figure 1. Distribution of study participants by age and gender
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According to the results of our study, the EBV seropreva-
lence in the Croatian population tends to increase progressively 
with age from 59.5% in the < 9 year age group to 98.3% in 
30–39 year olds, and remains stable thereafter. Similar results 
were found in a majority of other studies [2,3,12,13]. However, 
some studies showed a bimodal pattern of the increase in the 
EBV seropositivity. In Venezuela, the first peak occurred in 
children younger than 1 year, and the second one started after 
16 years [15]. In Spain, peaks were observed at the age of 2–4 
years and 14–18 years [1]. 
Our study showed that females had significantly higher IgG 
seroprevalence compared to males (93.1% and 89.9%, respec-
tively), which is similar to the results of other studies [16,17]. 
However, in some studies there was slightly higher EBV sero-
prevalence in females [18] or there was no difference in EBV 
seropositivity between genders [3].
Many observations implicate EBV in the pathogenesis of 
multiple sclerosis [9]. The evidence linking EBV infection to 
multiple sclerosis comes from epidemiological studies showing 
that nearly all multiple sclerosis adult patients are seropositive 
for EBV. In addition, a study conducted on pediatric patients in 
Canada found that 86% of the children with multiple sclerosis, 
irrespective of geographical residence, were seropositive for 
remote EBV infection, compared with only 64% of matched 
healthy controls [14]. Moreover, a study conducted in Germany 
showed similar results. The children with multiple sclerosis 
showed a near complete seropositivity for EBV VCA (98.6%) 
compared to 72.1% of controls, but did not display serologic 
evidence for a recent EBV infection [20]. In this study, EBV 
seropositivity of 100% was found in the group of patients with 
multiple sclerosis. However, due to a small number of par-
variations. In the Croatian adult general population, the overall 
IgG seropositivity was 95.9%, which is similar to the preva-
lence rate in other developed countries [1]. This study showed 
that 59.6% of Croatian children are infected with EBV by the 
age of 9 years and 79.0% by the age of 19 years. The results 
of the National Health and Nutrition Examination Surveys 
(NHANES) conducted in the United States showed similar 
seropositivity rates: 50% in the age group 6–8 years, 59% in 
the age group 12–14 years, and 89% in the age group 18–19 
years [2]. Other studies showed that most of the children are 
infected with EBV earlier in their life. A Thai study found a 
seroprevalence rate of 50.4% in children younger than 2 years of 
age, which increased and reached 97.6% in children by the age 
of 12–14 years [12]. Similarly, seroprevalence was more than 
50% before age 3 in Chinese children and exceeded 90% after 
age 8 years [13]. In addition, a high proportion of seroposi-
tive children younger than 9 years (96.3%) was reported in the 
Eastern Anatolian region of Turkey [14].
Table 1. Prevalence of EBV antibodies according to participant characteristics
Characteristics
Tested
N (%)
EBV VCA IgM
N (%) 95%CI P
EBV VCA IgG
N (%) 95%CI P
Overall 2022 (100) 182 (9.0) 7.8–10.3 1847 (91.4) 90.1–92.6
Gender
Male
Female
1104 (54.6)
918 (45.4)
90 (8.2)
92 (10.0)
6.6–9.9
8.2–12.2
0.160
992 (89.9)
855 (93.1)
87.9–91.6
91.4–94.5
0.008*
Age (years)
< 9
10–19 
20–29 
30–39 
40–49 
50–59 
60+ 
198 (9.8)
229 (11.3)
283(14.0)
343 (17.0)
288 (14.2)
318 (15.7)
363 (18.0)
37 (18.7)
52 (22.7)
30 (10.6)
25 (7.3)
12 (4.2)
13 (4.1)
13 (3.6)
13.5–24.8
17.4–28.7
7.3–14.8
4.8–10.6
2.2–7.2
2.2–6.9
1.9–6.0
< 0.001* 118 (59.6)
181 (79.0)
261 (92.2)
337 (98.3)
283 (98.3)
310 (97.5)
357 (98.3)
52.4–66.5
73.2–84.1
88.5–95.1
96.2–99.4
96.0–99.4
95.1–98.9
96.4–99.4
< 0.001*
Population group
Children/adolescents
Adult general population
Hemodialysis patients
Multiple sclerosis
Crohn›s disease
Heart transplant recipients
Hematological malignancies
295 (14.6)
1134 (56.1)
174 (8.6)
37 (1.8)
61 (3.0)
208 (10.3)
113 (5.6)
66 (22.4)
90 (7.9)
4 (2.3)
2 (5.4)
3 (4.9)
11 (5.3)
6 (5.3)
17.7–27.6
6.4–9.7
0.1–5.8
0.1–18.2
1.0–13.7
2.9–9.3
2.0–11.1
< 0.001*
201 (68.1)
1087 (95.9)
170 (97.7)
37 (100)
54 (88.5)
195 (93.8)
103 (91.2)
62.5–73.4
94.5–96.9
94.2–99.4
90.5–100
77.8–95.3
89.5–96.6
84.3–95.7 < 0.001*
EBV = Epstein-Barr virus, VCA = viral capsid antigen antibody, IgM = immunoglobulin M, IgG = immunoglobulin G, 95%CI = 95% conﬁdence interval
*statistical signiﬁcance
Figure 2. Epstein-Barr virus IgG avidity according to age
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to the frequent inability to detect virus in atherosclerotic lesions, 
some clinical studies have supported the atherogenic role of viral 
infections. The majority of studies have indicated that viral infec-
tions can promote evolution of atherosclerosis and acute coro-
nary events through production and release of pro-inflammatory 
cytokines. A study conducted in Saudi Arabia analyzed the EBV 
seroprevalence among patients with atherosclerotic vascular 
disease compared to healthy subjects. A higher percentage of 
patients showed EBV IgG antibodies; however, there was no 
significant difference between these groups [24]. In this study, 
heart transplant recipients showed a seroprevalence rate (93.8%) 
similar to the general adult population (95.9%).
In our study, the overall prevalence of IgM antibodies was 
9.0%, indicating an acute EBV infection. Since IgM antibod-
ies could be a false positive (hemodialysis patients, pregnant 
women), a sign of reactivation (immunocompromised 
patients), or a result of a polyclonal stimulation (cytomega-
lovirus infection, parvovirus B19), serology results should 
be interpreted with caution. Determination of IgG avidity in 
combination with classical serologic markers seems to be a 
reliable test for confirmation of primary EBV infection both in 
immunocompetent and immunocompromised patients [25]. In 
this study, acute primary infection detected by low AI was the 
most commonly documented in the age groups < 9 years and 
10–19 years, while all IgM positive participants older than 40 
years showed high AI indicating EBV reactivation, which is in 
concordance with other investigations [2,4].
CONCLUSIONS
The results of this study indicate that EBV is widespread in the 
Croatian population. More than half of the population (59.6%) 
is infected by the age of 9. Females had significantly higher IgG 
seroprevalence than males. Older age appeared to be the main 
risk factor for EBV seropositivity.
ticipants in this group, these results should be interpreted with 
caution. 
The increase in EBV activity as a consequence of the immune 
suppression, steroids, and other immunosupressants may cause 
a high risk of lymphoma development and promote the increase 
of certain types of cancers, including leukemia and multiple 
myeloma [21]. In this study, there was no difference in the EBV 
seropositivity among patients with hematological malignancies 
and the general adult population (91.2% vs. 95.9%). An Austrian 
study showed similar results (89% EBV IgG seropositivity in 
patients with chronic lymphocytic leukemia and 94% in healthy 
age-matched controls) [7]. In contrast, an Iranian study showed 
that EBV seropositivity was significantly higher in children with 
acute lymphoblastic leukemia [6].
A study conducted in Canada showed a high EBV serop-
revalence in patients with IBD. The prevalence of EBV in the 
IBD population aged 18–25 years was similar to that described 
in the general population (71%) and older than 25 years, sero-
positivity reached 100% [8]. Similarly, our results did not show 
higher IgG seroprevalence in this population group.
It has been documented that hemodialysis patients have 
impaired immune response, which predispose them to herpes 
virus infections, including EBV. Our study showed that EBV is 
highly prevalent in both hemodialysis patients (97.7%) and the 
adult population (95.9%). Two Iranian studies addressed the 
prevalence of EBV infection in hemodialysis patients. A study 
conducted from 2005 to 2008 showed 100% EBV seropositiv-
ity in both potential renal transplant donors and transplant 
recipients. A more recently published study (2011) showed a 
higher, but not statistically significant, difference in EBV IgG 
seroprevalence among pre-transplant patients and kidney 
donors (70% and 52%, respectively) [22,23]. 
Even though the role of viral infections in the pathogenesis of 
atherosclerosis and heart disease is still controversial in part due 
Table 2. Univariate logistic regression for risk of EBV seropositivity
Characteristics EBV IgM OR 95%CI OR EBV IgM AOR* 95%CI AOR EBV IgG OR 95%CI OR EBV IgG AOR 95%CI AOR
Female vs. male (ref.) 1.258 0.927–1.706 1.558 1.127–2.155
Age (years)
< 9 
10–19 
20–29 
30–39 
40–49 
50–59 
60 + 
1 (ref.)
1.278
0.515
0.342
0.189
0.185
0.161
0.796–2.050
0.306–0.868
0.199–0.588
0.095–0.373
0.095–0.358
0.083–0.312
1 (ref.)
2.556
8.043
38.079
38.372
26.271
40.448
1.669–3.915
4.784–13.522
16.183–89.600
15.160–97.127
12.322–56.010
17.149–94.882
Population group
Children/adolescents
Adult general population
Hemodialysis patients
Multiple sclerosis
Crohn›s disease
Heart transplant recipients
Hematological malignancies
1 (ref.)
0.299
0.081
0.198
0.179
0.193
0.194
0.211–0.423
0.029–0.228
0.046–0.846
0.054–0.591
0.099–0.377
0.081–0.462
1 (ref.)
0.710
0.236
0.383
0.356
0.501
0.380
0.437–1.155
0.078–0.713
0.086–1.693
0.104–1.211
0.238–1.054
0.154–0.936
1 (ref.)
10.815
19.875
NA
3.607
7.014
4.816
0.738–15.833
7.158–55.186
NA
1.581–8.228
3.801–12.943
2.406–9.640
1 (ref.)
1.421
1.828
NA
0.743
1.135
1.261
0.084–2.399
0.598–5.589
NA
0.300–1.843
0.558–2.306
0.585–2.717
EBV = Epstein-Barr virus, VCA = viral capsid antigen antibody, IgM = immunoglobulin M, IgG = immunoglobulin G, 95%CI = 95% conﬁdence interval, OR = odds 
ratio, AOR = odds ratios adjusted for age and gender
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percentage and respiratory mortality was attenuated after 
BMI adjustment. The authors concluded that both BMI and 
weight loss are predictors of cause-speciﬁc mortality in RA. 
Weight loss is a strong predictor of cardiovascular and cancer 
mortality, while underweight BMI is a stronger predictor of 
respiratory mortality.
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